Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder (MDD)

In brief

The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.

Key facts

Study ID

NCT01912196

Run by

MSI Methylation Sciences, Inc.

People needed

376

Starts

2013-10-01

Expected to finish

2015-09-01

Last updated by the study team

2016-03-18

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets the Diagnostic and Statistical Manual of Mental Disorder, 4th Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)
• A total score of 16 or higher on the Hamilton Rating Scale for Depression- 17 item version (HAM-D17) at the Screening and Baseline Visits, with a score of ≥2 on mood item 1.
• Have experienced 1-4 prior Major Depressive Episodes. Patients with more than 5 lifetime episodes (including current episode) will require discussion with the medical monitor prior to inclusion.
• Failed 1-3 treatment regimens in the current depressive episode
• Received an adequate dose and duration of Antidepressant Therapy (ADT) (on ADT for at least 6 weeks with a stable dose for at least 3 weeks)

You may not qualify if…

• Failed 4 or more adequate treatment regimens in current episode of depression
• patient may have a significant risk for suicidal behavior during the course of their participation in the study
• Intolerance to SAMe; Prior use of MSI-195
• History of any of the following psychiatric disorders: eating disorder within 6 months; obsessive compulsive disorder, psychotic disorder, bipolar disorder, mental retardation, dementia or other forms of cognitive impairment at any time or alcohol or substance abuse
• >3X upper limit of normal (ULN) Alkaline Phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT); >1.5X ULN total bilirubin
• Pregnant or lactating women
• Any history of seizures, excluding febrile seizures
• Known positivity for human immunodeficiency virus

Where it is running

• MSI Investigational Site — Birmingham, Alabama, United States
• MSI Investigational Site — Encino, California, United States
• MSI Investigational Site — Escondido, California, United States
• MSI Investigational Site — Garden Grove, California, United States
• MSI Investigational Site — Los Alamitos, California, United States
• MSI Investigational Site — Los Angeles, California, United States
• MSI Investigational Site — National City, California, United States
• MSI Investigational Site — Newport Beach, California, United States
• MSI Investigational Site — Oakland, California, United States
• MSI Investigational Site — Oceanside, California, United States
• MSI Investigational Site — Torrance, California, United States
• MSI Investigational Site — Jacksonville, Florida, United States
• MSI INvestigational Site — Kissimmee, Florida, United States
• MSI Investigational Site — Lauderhill, Florida, United States
• MSI Investigational Site — Orlando, Florida, United States
• MSI Investigational Site — Atlanta, Georgia, United States
• MSI Investigational Site — Hoffman Estates, Illinois, United States
• MSI Investigational Site — Towson, Maryland, United States
• MSI Investigational Site — Flowood, Mississippi, United States
• MSI Investigational Site — Las Vegas, Nevada, United States
• MSI Investigational Site — Marlton, New Jersey, United States
• MSI Investigational Site — Albuquerque, New Mexico, United States
• MSI Investigational Site — New York, New York, United States
• MSI Investigational Site — Rochester, New York, United States
• MSI Investigational Site — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.